Background and Purpose-Poly(ADP-ribose) polymerase-1 (PARP-1) is involved in ischemic preconditioning of the heart and cultured neurons, but its role in brain ischemic preconditioning is unknown. Summary of Report-We report that 5-minute bilateral common carotid artery occlusion (BCCAO) in the mouse prompted reduction of infarct volumes triggered 24 hours later by 20-minute middle cerebral artery occlusion (MCAO). Pharmacological PARP-1 inhibition between BCCAO and MCAO did not impair preconditioning. The contents of the PARP-1 substrate NAD, those of its product poly(ADP-ribose), caspase-3 activation, and PARP-1 expression did not change after BCCAO within the preconditioned tissue. PARP-1 KO mice were similarly protected by the 5-minute BCCAO. Conclusion-Data demonstrate that, at variance with the heart, PARP-1 is dispensable for brain ischemic preconditioning. (Stroke. 2010;41:181-183.) 
I schemic preconditioning (IPC) occurs in animals and humans affected by cardiovascular disorders. Understanding the biochemical events activated by IPC is of relevance to stroke therapy. 1 Poly(ADP-ribose) polymerase-1 (PARP-1) uses nicotinamide adenine dinucleotide (NAD) to form poly(ADP-ribose) (PAR) and is a fundamental mediator of experimental stroke injury. 2 Prior work indicates that myocardial IPC worsens infarct in PARP-1 KO mice, and the PARP-1 inhibitor 3-animobenzamide impairs heart preconditioning in WT animals. 3 Conversely, caspase-3-dependent PARP-1 cleavage underlies IPC in cultured neurons. 4 PARP-1 cleavage also occurs in Zincpreconditioned cultured neurons, 5 but not in ischemically preconditioned retinas. 6 We sought to determine whether PARP-1 is involved in brain ischemic preconditioning.
Materials and Methods
C57Bl/6 male PARP-1 KO and WT mice (Harlan; Milan, Italy) obtained from homozygous breeding pairs were used. For IPC, we simplified an IPC protocol described by Cho and colleagues. 7 Mice were anesthetized and common carotid arteries occluded (BCCAO) for 5 minutes with microclips. After 24 hours, mice underwent transient middle cerebral artery occlusion (MCAO) as reported. 8 Mice were killed by decapitation and their brains frozen in liquid nitrogen to avoid postmortem changes. NAD and adenosine triphosphate (ATP) were measured in the preconditioned striata. To avoid postmortem changes striata were collected from coronal brain slices, cut with cryostat, and immediately dissolved in 0.4 N HClO 4 to avoid nucleotide hydrolysis. Nucleotide were measured in the striatum because, as evidenced by histological analysis, together with the deeper layers of the adjacent parietal cortex it was the preconditioned brain region. Yet, it was impossible to collect the ischemic parietal cortex because it was not feasible to identify the boundaries between the preconditioned and nonpreconditioned cortex in the frozen brain.
Indirect infarct determination, Western blotting, NAD, and ATP measurement were conducted as described. 9 Infarcts were measured 3 days after MCAO to rule out transient neuroprotection. The anti-PAR antibody and the Caspase-3 activity determination kit were from Alexis, the anti-PARP-1, and anti-caspase-3 antibodies were from Cell Signaling.
Results
Five-minute BCCAO had no effect on infarct volumes in mice subjected to 2-hour MCAO (74Ϯ2 in sham and 69Ϯ8 mm 3 in preconditioned mice; nϭ5/group) or 1-hour MCAO (57Ϯ7 in sham and 55Ϯ8 mm 3 in preconditioned mice; nϭ5/group) (not shown). Five-minute BCCAO showed a tendency toward neuroprotection with a 30 minutes MCAO (46Ϯ8 in sham and 39Ϯ9 mm 3 in preconditioned mice; nϭ8/group; Figure 1B and 1C) and afforded significant protection with a 20-minute MCAO (27Ϯ3 in sham and 10Ϯ0.8 mm 3 in preconditioned mice; nϭ8/group; Figure 1D and 1E).
Next, mice were injected with the PARP-1 inhibitor N- 10 in the time window comprised between BCCAO and MCAO ( Figure 1A ). PJ34 was chosen because of its potency (IC 50 110 nmol/L) and neuroprotective activity. 11 Mice received a neuroprotective dose of 20 mg/kg i.p. 11 at 0, 8, and 16 hours after BCCAO. In preconditioned animals, PJ34 had no effect on infarct volumes (10Ϯ1.7 mm 3 ; nϭ10; Figure 1D and 1E) or areas ( Figure 1D and 1F). PJ34 (20 mg/Kg i.p.) was also injected 24, 16, and 8 hours before a 20-minute MCAO in naive mice. PJ34 pretreatment did not affect infarct volumes (25Ϯ5 in vehicle-and 23Ϯ6 mm 3 in PJ34-pretreated mice; nϭ5/group; not shown), thereby excluding drug carryover during and after MCAO.
Striatal PAR content was not changed after 5 minutes BCCAO or the following 30 minutes (Figure 2A and 2B) , 4, 6, 12, and 24 hours of reperfusion (not shown). PAR contents did not increase even after longer BCCAO of 10 and 15 minutes ( Figure 2C and 2D) . Findings indicate that PARP-1 is not activated by 5-to 15-minute BCCO. Although PARP-1 activation prompts NAD and ATP consumption, 12 striatal NAD contents were not affected by BCCAOϮreperfusion or by 60-minute pretreatment with 20 mg/kg PJ34 (Figure 2E ). BCCAO prompted a drop of striatal ATP content that vanished on 15 minutes reperfusion ( Figure 2F ). Neither the active fragment of Caspase-3 ( Figure 2G and 2H) nor caspase-3 activity ( Figure 2I ) increased in the preconditioned brain tissue in the time window comprised between BCCAO and MCAO. Accordingly, the 85-kDa PARP-1 fragment, a prototypical caspase-3 proteolytic product, was not present in the preconditioned brain tissue ( Figure 2L ).
In keeping with prior work, 2 infarct volumes in KO mice were smaller than in WT (19Ϯ2 versus 27Ϯ3 mm 3 , respectively; PϽ0.05, Student t test). Five-minute BCCAO protected KO mice from 20 minutes MCAO (infarct volumes 9Ϯ1.6 mm 3 , nϭ7, Figure 3A and 3B). The extent of protection by preconditioning in KO animals was similar to that in WT (59 and 63%, respectively).
Discussion
We report that PARP-1 expression and activity are not required for IPC in the mouse brain. Given that the PARP-1 inhibitor 3-aminobenzamide impairs myocardial IPC, 3 data suggest that ischemic tolerance of the heart mechanistically differs from that of brain. Evidence that in PARP-1 KO mice IPC reduces heart ischemic tolerance 3 but increases that of brain corroborates this hypothesis. Caution, however, should be exercised when comparing IPC in different tissues. Our findings indicate that PARP-1 is dispensable for brain ischemic preconditioning, but do not exclude the possibility that it contributes to IPC when activated.
Caspase-3-dependent PARP-1 cleavage underlies IPC of cultured neurons, 4 as confirmed by Lee and colleagues. 5 Caspase-3 activation is also involved in brain IPC of hypertensive rats. 13 The findings that the active fragment of caspase-3, its enzymatic activity or PARP-1 cleavage do not increase in preconditioned mouse brains suggest that caspase-3 activation is not a prerequisite for brain ischemic preconditioning.
Overall, data suggest that PARP-1 plays different roles during IPC or maturation of brain infarct, and furthers our understanding of the molecular signaling responsible for setting the threshold of ischemic tolerance. Given that PARP-1 inhibitors are being investigated in clinical trials, 2,10 our findings may have important clinical implications.
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